CG Oncology, Inc.
CGON
Positions held
Your positionsCGON isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- CG Oncology operates in the biotechnology sector, which is known for its potential to innovate and address unmet medical needs, particularly in oncology treatments.
- Revenue increased by 7% in the latest quarter, reaching $1.2 million compared to $1.1 million in the prior quarter.
- The company's target mean price is $91.08, indicating significant upside potential from its current valuation.
- CG Oncology faces significant financial challenges, including a negative operating margin of -7467.7% in the latest quarter, which raises concerns about sustainability.
- The company reported a net income loss of $79.06 million in the most recent quarter, reflecting ongoing operational difficulties.
- With a score of 'Strong Sell' and a score of -19.00, market sentiment is heavily negative, indicating a lack of confidence among investors.
Fundamentals
| Market cap | $5.61B | Enterprise value | $4.59B | Trailing P/E | — | Forward P/E | -20.94 |
| PEG | — | Price / book | 5.43 | Beta | 0.28 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | -74.7% |
| Profit margin | 0.0% | ROE | -26.4% | ROA | -17.7% | Debt / equity | 0.01 |
| Current ratio | 22.22 | Free cash flow | -$113.71M | Analyst recommendation | none | Mean target | $91.08 |
| 52w high | $80.97 | 52w low | $35.80 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2M | $1.1M | $2.3M | $1.7M | $0.0M | — |
| Op margin | -7467.7% | -6130.1% | -2097.3% | -3069.0% | — | — |
| Net income | -$79.1M | -$60.2M | -$41.3M | -$43.8M | -$41.4M | — |
| Gross margin | -239.2% | -173.5% | -32.2% | 5.3% | — | — |
| Gross profit | -$2.8M | -$1.9M | -$0.7M | $0.1M | $0.0M | — |
| Operating income | -$86.4M | -$66.4M | -$48.7M | -$51.1M | -$48.7M | — |
- Revenue +7% vs prior quarter ($1.2M vs $1.1M).
- Gross margin -239.2% (was -173.5% prior quarter).
- Operating margin compressed to -7467.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $4.0M | $1.1M | $0.2M | $0.2M | — |
| Op margin | -4722.1% | -10067.3% | -27180.9% | -18453.4% | — |
| Net income | -$161M | -$88.0M | -$48.6M | -$35.4M | — |
| Gross margin | -15.0% | 100.0% | 100.0% | — | — |
| Gross profit | -$0.6M | $1.1M | $0.2M | — | — |
| Operating income | -$191M | -$115M | -$55.4M | -$35.2M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-11 · 3 Stocks Call Traders Are Targeting Today
2026-09-03 · CG Oncology (CGON) Stock Looks Fully Priced After A 160% Run
2026-08-07 · BofA Adjusts Price Target on CG Oncology to $88 From $87
2026-08-07 · RBC Adjusts PT on CG Oncology to $79 From $81, Maintains Outperform Speculative Risk Rating
2026-08-06 · CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates
2026-08-06 · CG Oncology Q2 Net Loss Widens
2026-08-06 · CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-07-28 · CG Oncology Phase 3 Study Shows Durable Responses in High-Risk Bladder Cancer
2026-07-27 · CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
2026-07-16 · ANI Pharmaceuticals Plans to Appeal Trial Court Rulings in CG Oncology Case
2026-07-16 · ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter
Price (daily)
Full chart · RSI · MACD · patterns